

**Freedom of Information Act 2000 - Request Reference FoI/23/032**  
**Spinal Muscular Atrophy**

We have a freedom of information request related to the diagnosis and treatment of Spinal Muscular Atrophy. Your answers to the following questions would be greatly appreciated.

1. How many patients have a current diagnosis for Spinal Muscular Atrophy (ICD-10 Code G12.0, G12.1, G12.8 and G12.9) at your trust?

Distinct patients in period coded with diagnosis of Spinal Muscular Atrophy: 11

NB: Based on a Spinal Muscular Atrophy diagnosis codes in any diagnosis position in all Episodes. Based on Coding as of: 7 Feb 2023

2. How many patients have been treated in the last 4 months (September to December 2022) with the following products:

- Evrysdi (Risdiplam) - total patients - 1
- Spinraza (Nusinersen) - total patients - 0
- Zolgensma (Onasemnogene) - total patients - 0
- Evrysdi (Risdiplam) - new\* patients - 0
- Spinraza (Nusinersen) - new\* patients - 0
- Zolgensma (Onasemnogene) - new\* patients - 0

\*new patients are defined as patients who were not treated with any of Spinraza (Nusinersen), Evrysdi (Risdiplam) or Zolgensma (Onasemnogene) in the previous 4-month period (May to August 2022).

3. Of the total patients treated in the last 4 months (September to December 2022) with Evrysdi (Risdiplam), please provide the number of patients that were treated with Spinraza (Nusinersen) in the previous 4 months (May to August 2022).

0

4. Of the total patients treated in the last 4 months (September to December 2022) with Zolgensma (Onasemnogene), please provide the number of patients that were treated with Spinraza (Nusinersen) in the previous 4 months (May to August 2022).

0

5. How many patients have been treated with Zolgensma (Onasemnogene) in the last 12 months (January to December 2022)?

0